INDP — Indaptus Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1857044 ·
Last close
$1.11
Market Cap
$125.70M
52W High
$3.84
52W Low
$0.92
ADV30
86,163
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -2,159,588 | -2,541,070 | 2,180,856 | 1,497,635 | 932,999 |
| Dec 2025 | 0 | — | -8,155,704 | -8,112,450 | 9,310,168 | 8,507,628 | 6,158,575 |
| Sep 2025 | 0 | — | -2,648,487 | -2,975,117 | 6,840,052 | 5,825,639 | 2,234,325 |
| Jun 2025 | 0 | — | -4,456,763 | -5,228,919 | 6,839,207 | 6,157,701 | 8,512,563 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-14,823,256
Investing CF
$0
Financing CF
$17,544,131
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-30.07
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-81,288,099
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-19,833,513
Pretax Income TTM
$-20,848,916
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -19,833,513 | -20,848,916 | 9,310,168 | 6,158,575 | — | -14,823,256 |
| Dec 2024 | 0 | -15,365,751 | -15,022,027 | 7,338,756 | 3,393,881 | — | -12,323,188 |
| Dec 2023 | 0 | -16,378,474 | -15,423,471 | 14,923,878 | 2,847,380 | — | -13,405,315 |
| Dec 2022 | 0 | -14,910,906 | -14,322,798 | 28,063,806 | 3,433,341 | — | -13,078,347 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.39
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CYPH | CYPHERPUNK TECHNOLOGIES INC. | $123.50M | $1.16 | — |
| PLYX | Polaryx Therapeutics, Inc. | $122.15M | $2.58 | — |
| VTVT | vTv Therapeutics Inc. | $130.61M | $33.16 | — |
| QTTB | Q32 Bio Inc. | $120.22M | $7.09 | — |
| DERM | Journey Medical Corp | $131.79M | $6.12 | — |
News headlines (Yahoo Finance, 1h cache)
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-15 11:00 · Yahoo
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
2025-12-29 12:00 · Yahoo
Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit
2025-11-17 13:00 · Yahoo
Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
2025-11-12 13:30 · Yahoo
Wall Street Set to Open Higher Friday; Nonfarm Payrolls Fall Well Short of Forecasts
2025-09-05 13:22 · Yahoo
Indaptus Therapeutics Provides Clinical Update
2025-09-04 20:01 · Yahoo
Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference
2025-09-02 20:05 · Yahoo
Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
2025-08-13 12:00 · Yahoo
Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants
2025-07-01 12:14 · Yahoo
Indaptus Therapeutics Announces Reverse Stock Split
2025-06-25 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.